Education:
M.D. - 1988-1992; -Medical School: University of Liege, School of Medicine, Liege, Belgium,
Post-graduate Training:
Internal Medicine Residency: University of Liege, School of Medicine, Liege, Belgium and Case Western Reserve University/University Hospitals of Cleveland
Hematology/Medical Oncology Fellowship: Case Western Reserve University, Cleveland, Ohio.
Board Certifications:
Belgium (European Union) Cert. in Internal Medicine (Hematology/Oncology)
(Diplome d’etudes specialises) (1997)
Diplomate American Board of Internal Medicine (2000)
Diplomate American Board of Medical Oncology (2001)
Appointments:
· Assistant Professor of Medicine - Case Western Reserve Univeristy: 2000- present
· Member - Comprehensive Cancer Center, University Hospitals of Cleveland and Case Western Reserve University: 2000- present
· Developmental Therapeutics Program - Comprehensive Cancer Center, University Hospitals of Cleveland and Case Western Reserve University: 2000- present
Awards:
Best Medical Student Award (La Plus Grande Distinction): University of Liege, School of Medicine, Belgium, 1989, 1991, 1992.
American Academy of Dermatology and International Society of Dermatology Young Investigator Travel Award: 1992.
Berlex Oncology Foundation Award (for Pharmacology of Anticancer Drugs), U.S.A. 1997.
Murphy-Weisman Fellowship Award. Case Western Reserve University, 1997.
Orthobiotech Travel Grant Award, 1998.
MetroHealth Medical Center/Case Western Reserve University Scientific Achievement Award (in Recognition of Outstanding Achievement in Biomedical Research), 1998.
Rhone-Poulenc-Rorer Annual Oncology Award, 1999.
Memberships:
Belgian Society of Internal Medicine
American Society of Clinical Oncology
American Association for Cancer Research
Eastern Cooperative Oncology Group
Editorial Board
2004- present American Journal of Clinical Oncology
Journal Peer Reviewer (ad hoc):
Journal of Clinical Oncology
Cancer
American Journal of Hematology
The Cancer Journal
Cancer Chemotherapy and Pharmacology
American Journal of Respiratory and Critical Medicine
Cancer Research
Publications (Articles):
Pierard GE, Dowlati A. Effets deleteres des gaz de combat vesicants Revue Medical de Liege 1989;4: 133-137.
Laso-Dosal F, Arrese Estrada J, Ben Mosbah T, Dowlati A, Damseaux M, Melotte P. L’epithelioma basocellulaire Revue Medicale de Liege 1989; 23: 705-716
Pierard GE, Pierard-Franchimont C, Nickels-Read D, Dowlati A, Dowlati Y, Ekoude IB, PorignonD. La tuberculose cutanee, une maladie oubliee? Revue Medical de Liege 1990; 9: 413-421.
Pierard GE, Arresse JE, Dowlati A, Daskaleros PA, Rodriguez C.Effects of softened and unsoftened fabrics on infant skin International Journal of Dermatology 1994; 33: 138-141.
Louis R, Dowlati A, Weber T, Bury T, Corhay JL, Radermecker MF. Modulation on immunological histamine release from human lung fragments by stem cell factor, IL-3, IL-5 and GM-CSF; comparison to human leukocytes. International Archives of Allergy and Immunology 1994; 105: 18-25.
Dowlati A, Honore P, Damas P, Deprez M, Delwaide J, Fillet G, Beguin Y. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation Transplantation 1995; 60: 106-109.
Pierard GE, Letawe C, Dowlati A, Pierard-Franchimont C. Effect of hormone replacement therapy for menopause on mechanical properties of the skin Journal of the American Geriatrics Society 1995; 43: 662-665.
Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P. Staging of non-small cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. European Journal of Nuclear Medicine 1996; 23: 204-206.
Dowlati A, Loo M, Radermecker M, Fillet G, Beguin Y. Soluble transferrin receptor in bronchoalveolar lavage fluid and serum of lung cancer patients British Journal of Haematology 1996; 93 (suppl 2): 369A.
Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, Limet R, Rigo P, Radermecker M. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging European Respiratory Journal 1996; 9: 410-414.
Dowlati A, Bury T, Corhay JL, Weber T, Mendes P, Radermecker M. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung cancer: diagnostic value, relation to serum neuron specific enolase and staging Cancer 1996; 77: 2039-2043.
Dowlati A, Bury T, Corhay JL, Wber T, Lamproye A, Mendes P, Radermecker M. Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease Thorax 1996; 51: 1270-1272.
Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, Schoffers J, Limet R, Albert A, Rigo P, Radermecker M. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer European Respiratory Journal 1996; 9: 2560-2564.
Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report Thorax 1997; 52: 187-189.
Dowlati A, R’Zik S, Fillet G, Beguin Y. Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoeitin production British Journal of Hematology 1997; 97: 297-299.
Dowlati A, Loo M, Bury T, Fillet G, Beguin Y. Soluble and cell-associated transferrin receptor in lung cancer British Journal of Cancer 1997; 75: 1802-1806.
Bury T, Dowlati A, Paulus P, Corhay JL, Hustinx R, Ghaye B, Radermeker M, RigoP. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer European Respiratory Journal 1997; 10: 2529-2534.
Baron FA, Hermanne JP, Dowlati A, Weber T, Thiry A, Fassotte MF, Fillet G,Beguin Y. Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplantion 1998; 21: 951-954.
Levitan N, Dowlati A, Tahsildar H, McKenney J, Remick SC. A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support in advanced non-small cell lung cancer: results of a phase II study. Lung Cancer 1998; 22: 227-234.
Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm A. Rates of thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using medicare claims data Medicine 1999; 78: 285-291.
Remick SC, Sedransk N, Haase R, Craffey M, Subramanian N, Dowlati A, Nazeer T, Blanchard C, Mastrianni D, Balducci L, Horton J, Ruckdeschel J. Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies Drugs 1999; 58 Suppl 3: 99-107.
Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer Journal of Laboratory and Clinical Medicine 1999; 134: 405-409.
Levitan A, Dowlati A, Shina D, Craffey M, Mackay W, Devore R, Jett J, Remick, DeVore R, Chang A, Johnson D. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation and for limited stage small-cell lung carcinoma. Journal of Clinical Oncology 2000; 18: 1102-1109.
Remick SC, Patnail M, Ziran NM, Liegmann KR, Dong J, Dowlati A, Yao Y, Abdul Karim FW, Giam CZ. Human Herpesvirus-8-associated disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors. American Journal of Medicine, 2000; 108: 660-664.
Dowlati A, Levitan N, Gordon N, Hoppel CL, Gosky DM, Remick SC, Ingalls ST, Berger SJ, Berger NA. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2001; 47: 141-148.
Dowlati A, Crosby L. Remick SC, Makkar V, Levitan N. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer: the use of complete response rate as the primary endpoint in phase II trials. Lung Cancer 2001; 32: 155-162.
Dowlati A, Hoppel CL , Ingalls ST, Majka S, Li X, Sedransk N, Spiro T, Gerson SL, Ivy P, Remick SC. Phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC 655649) given daily for 5 consecutive days. Journal of Clinical Oncology 2001;19(8): 2309-2318.
Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Willson JKV. Sequential tumor biopsies in early phase clinical trials of anti-cancer agents for pharmacodynamic evaluation. Clinical Cancer Research 2001; 7: 2971-2976.
Dowlati A, Cooney M, Robertson K, Petros WP, Stratford M, Jesberger J, Rafie N, Lewin J, Overmoyer B, Makkar V, Buchter C, Stambler B, Taylor A, Wass J, McCrae K, Remick SC. Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A4 Phosphate (CA4P) in patients with advanced cancer. Cancer Research 2002; 62: 3408-3416.
Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ghannoum M, Dowlati A, Renne R, Arts E, Whalen C, Lederman MM, Remick SC. Therapeutic challenges of AIDS-related non-Hodgkin’s lymphoma in the United States and East Africa. Journal of the National Cancer Institute, 2002; 15;94(10):718-32.
Dowlati A, Lazarus HM, Hartman P, Jaccoberger JW, Whitacre C, Gerson SL, Ksenich P, Copper BW, Frisa PS, Gottlieb M, Murgo AJ, Remick SC. Phase I and correlative study of combination bryostatin 1 and vincristine in refractory B-cell malignancies. Clinical Cancer Research, 2003; 9: 5929-5935.
Dowlati A, Levitan N. Combination chemotherapy with topotecan for non-small cell lung cancer. Lung Cancer. 2003 Aug;41 Suppl 4:S23-6.
Cooney MM, Radivoyevitch, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clinical Cancer Research. In press. January 2004.
Ingalls ST, Li X, Stefan TL, Dowlati A, Remcik SC, Hopple CL. Determination of the rebeccamycin analog NSC 655649 in human plasma specimens by reverse-phase high performance liquid chromatography. Submitted.
Surmacz TA, Satoh TH, Dowlati A, Remick SC. Whitacre CM. Activation of protein kinase C by bryostatin-1 induces p53 in peripheral blood mononuclear cells from patients with chronic lymphocytic leukemia. Submitted.
Dowlati A, Nethery D, Kern JA. Combined inhibition of EGFR and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Submitted.
Bacus S, Xia W, Burris H, Hurwitz H, Dees C, Dowlati A, O’Neil B, Overmoyer B, Liu L, Smith D, Koch K, Stead A, Mangum S, Greco F, Harris J, Spector N. A Study of the biological effects of GW572016, a reversible inhibitor of EGFR (ErbB1) and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Submitted
Dowlati A, Ardizzoni A. Prolonged topotecan treatment in patients with relapsed small cell lung cancer: a meta-analysis of individual patient data from 6 prospective studies. Submitted.
Tserng KI, Overmoyer B, Dowlati A, Makkar V, McPeak J, Hezel L, Ingalls ST, Robertson K, Remick SC, Hoppel CL. Pharmacokinetics and drug interactions of the angiogenic inhibitor SU5416, in cancer patients. Submitted.
Physician Initiated Clinical Trials - Principal Investigator-active and closed studies
Prinicipal Investigator: Afshin Dowlati, MD: A phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC 655 649) given daily for 5 consecutive days. (NCI UO1 cooperative agreement). Case Western Reserve University Protocol CWRU 4Y96
Principal Investigator: Afshin Dowlati, MD: A phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies. (NCI UO1 cooperative agreement). Case Western Reserve University Protocol CWRU 3Y97
Principal Investigator: Afshin Dowlati, MD: A phase I pharmacodynamic study of SU5416. Case Western Reserve University Protocol CWRU 1299 (NCI U01 cooperative agreement).
Principal Investigator: Afshin Dowlati, MD: A randomized phase II trial of two different schedules of administration of rebeccamycin analog in advanced non-small cell lung cancer. Case Western Reserve University Protocol CWRU 1299
Principal Investigator: Afshin Dowlati, MD: Phase II and pharmacokinetic trial of rebeccamycin analog in hepatobiliary cancers. Case Western Reserve University Protocol CWRU 1299.
Laboratory Co-Chair: Afshin Dowlati, MD: ECOG 4599 - A randomized phase III trial of carboplatin/taxol with or without Anti-VEGF monoclonal antibody in advanced non-small cell lung cancer.
Principal Investigator: Afshin Dowlati, MD: Phase II study of thalidomide as maintenance therapy for responding small cell lung cancer.
Co-Principal Investigator: Afshin Dowlati, MD: 11C Topotecan PET imaging as a biochemical predictor of response to topotecan. Case Western Reserve University Protocol CWRU 6Y02
Co-Principal Investigator (Multi-insititutional study): Afshin Dowlati, MD: A phase I open-label, safety, pharmacokinetics and pharmacodynamics study of multiple doses of GW572016 to examine the inhibition of EGFR/erbB-2 phosphorylation in cancer patients with solid tumors.
Co- Principal Investigator (Bi-institutional study): A phase I, open label, multiple dose, dose escalation study of GW786034 in patients with solid tumors.
Books (chapters):
A. Dowlati, C. Pierard-Franchimont, GE Pierard: The diagnostic value of histopathological changes in the stratum corneum. In: Dermatology in Europe. Editor: Emiliano Panconesi. Blackwell Scientific Publications, Oxford, UK 1989.
A. Dowlati, SC Remick: AIDS-related malignancies. In: Current Cancer Therapeutics. Editors: Kirkwood J et al. 3rd Edition 1998. Current Medicine Inc., Philadelphia, PA.
A. Dowlati, Eakin R, Kinsella T. Chemotherapy-Radiation interactions. In: Lung Cancer: Principles and Practice, eds Pass H et al. 2nd Edition 2000. Lippincott-Raven,
Philadelphia, PA.
Abstracts (posters and oral presentations):
Dowlati Y, Dowlati A. Lipoid Proteinosis-Relative response to etretinate therapy. 40th Annual Meeting of the American Academy of Dermatology. San Antonio, Texas. 1987.
Dowlati A, Honore P, Damas P, Fillet G, Beguin Y. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. 10 minute presenation. Belgian Week of Gastroenterology. Knokke, Belgium. 1995.
Dowlati A, Loo M, Radermecker M, Fillet G, Beguin Y. Soluble transferrin receptor in bronchoalveolar lavage fluid and serum of lung cancer patients. Abstract 369. 2nd Meeting of the European Haematology Association, Paris, France. 1996.
Baron F., Hermanne JP, Dowlati A, Weber T, Thiry A, Fassotte M, Fillet G, BeguinY. Bronchiolitits obliterans organizing pneumoni (BOOP) and ulcerative colitits after allogeneic bone marrow transplantation. Abstract. 13th Annual Meeting of the European Group for Blood and Marrow Transplantation, Aix-les-Bains, France. 1996
Dowlati A, Remick SC, Hoppel C. Phase I study of Rebeccamycin given daily for 5 days. National Cancer Institute Spring 1998 Phase I Meeting, Bethesda, Maryland. 1998.
Dowlati A, Remick SC, Majka S, Ingalls S, Hoppel C, Spiro T, Gerson S, Willson JKV. Phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC 655649) given daily for 5 consecutive days. Proc Am Soc Clin Oncol 1999, abstract 694
Remick SC, Dowlati A, Ingalls S, Hoppel C, Spiro T, Gerson S, Willson JK. Phase I pharmacokinetic study of oral declopramide with cisplatin in patients with advanced cancer. Proc Am Soc Clin Oncol 1999, abstract 649.
Levitan N, Dowlati A, Craffey M, Remick SC, Shina D, Devore, Jett J, Chang Johnson D. A multiinstitutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation and filgrastim support for limited-stage small cell lung carcinoma. Proc Am Soc Clin Oncol 1999, abstract 1809.
Schilling RA. Subramanian N, Dowlati A, Gordon S, Ramnes C, sedransk N, Lederman M, Remick SC. A composite clinical stage for AIDS-related Kaposi’s Sarcoma. A refinement of the AIDS Clinical Trials Group (ACTG) clinical staging classification. The National AIDS Malignancy Conference. Bethesda, Maryland 1999.
Ziran N, Patnaik M, Liegmann, KR, Chandran B, Yao Y, Giam C-Z, Dowlati A, Abdul-Karim FW, Remick SC. HHV-8 related disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors. The National AIDS Malignancy Conference, Bethesda, Maryland 1999.
Dowlati A, Robertson K, Ksenich P, Jacobberger J, Whitacre C, Cooper B, Spiro T, Lazarus H, Gerson S, Murgo A, Sedransk N, Remick SC. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies. AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Washington D.C., November 16-19, 1999. Clinical Cancer Research 1999, Suppl Nov, abstract 113.
Dowlati A, Majka S, Hoppel C, Ingalls S, Spiro T, Gerson S, Ivy P, Willson JKV, Sedransk N, Remick SC. The activity and pharmacokinetics of rebeccamycin analog in cancer of the biliary tract during a phase I trial. AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Washington D.C., November 16-19, 1999. Clinical Cancer Research 1999, Suppl Nov, abstract 4.
Remick SC, Dowlati A, Robertson K, Spiro T, Connell C, Levitan N, Stratford M. Phase I pharmacokinetic study of single dose intravenous combretastatin A4 prodrug (CA4P) in patients with advanced cancer. AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Washington D.C., November 16-19, 1999. Clinical Cancer Research 1999, Suppl Nov, abstract 16.
Surmacz TA, Dowlati A, Remick SC, Whitacre CM. Effect of bryostatin on topoisomerase II and p53 in PBMC from patients with refractory B-cell malignancies. Proc Am Assoc Cancer Res (AACR) 2000, abstract 929.
Levitan N, Dowalti A, Hoppel C, Ingalls S, Inverso J, Berger N, Remick SC. Phase II pharmacokinetic trial 9-aminocamptothecin colloidal dispersion 120 hr continuous infusion in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000, abstract 1963.
Wass J, Overmoyer B, Dowlati A, Makkar V, Robertson K, Ksenich P, Remick S, McCrae K. Circulating adehesion molecules in patients receiving SU5416. AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Miami Beach Florida, October 29-November 2, 2001. Clinical Cancer Research 2001, Suppl Nov, abstract 56.
Dowlati A, Nethery D, Liu J, Kern A. Combined inhibition of epidermal growth factor receptor (EGFR) and JAK/STAT signaling results in superior growth inhibition in A431 cell line as compared to single agent therapy. Proc Am Assoc Cancer Res, 2003, abstract 4006.
Cortas T, Ness A, Chapman R, Remick S, Levitan N, Schmidt C, Patrick L, Xu N, Ivy P, Dowlati A. Randomized phase II trial of 2 different administration schedules of rebeccamycin analogue (RA) as 2nd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, abstract 2686
Dowlati A, Posey J, Ramanathan RK, Rath L, Sellers S, Schmotzer A, Ingalls S, Hoppel C, Ivy P, Remick SC. Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. Proc Am Soc Clin Oncol 2003, abstract 1070.
Spector N, Raefsky E, Hurwitz H, Hensing T, Dowlati A, Dees C, O'Neil B, Smith DA, Mangum S, Burris HA. Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc Am Soc Clin Oncol 2003, abstract 772.
Department of Medicine|
11100 Euclid Avenue| Cleveland, Ohio 44106
